ABSTRACT
The COVID-19 pandemic has caused changes in respiratory infectious disease patterns. We analyzed de-identified data of microbiology assays of nasopharyngeal samples and blood samples of children with acute respiratory infection (ARI) visited Vinmec Times City International hospital in Hanoi, Vietnam from January 2019 to December 2023 to examine the overall pattern of viral and bacterial emerging pathogens associated with ARI in children before, during and after the COVID-19 pandemic. The data was aggregated by month and time series analysis and visualization was done. Bacterial Polymerase Chain Reaction (PCR) panel was done for 4125 samples, Mycoplasma pneumonia (MP) IgM was done for 5049 samples, bacterial culture was done for 10280 samples and viral PCR or rapid test was done for 42041 samples. After the COVID-19 pandemic, Haemophilus influenzae (HI) and Streptococcus pneumoniae (SP) have re-emerged as epidemic pathogens associated with lower respiratory tract infection (LRI). Influenza type A and type B have reestablished regular cycles of peaks in winter-spring months after an early rebound together with an unprecedented newly emergence of Human Adenovirus (HAdV) soon after the relief of COVID-19 restriction. Late after the COVID-19 pandemic, from middle of 2023, atypical pneumonia pathogen Mycoplasma pneumonia (MP) has emerged remarkably and becoming epidemic and there was also a small, brief emergence of Chlamydophila pneumoniae (CP) infection. Our data is useful to understand the influence of COVID-19 pandemic on the emergence or re-emergence of viral and bacterial respiratory infection pathogens in children and is useful for disease surveillance and public health intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was approved by Vinmec Ethical Committee (ref No 110/2024/CN/HDDD VMEC). Informed consent was not required for secondary analysis and report of de-identified data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
Data cannot be shared publicly because the data is the property of Vinmec Healthcare System. Data are available from Vinmec Ethics Committee (contact via corresponding author) for researchers who meet the criteria for access to data.
